Complete Response Letter NDA 505b1 217382 (Jun 2, 2025)

Summary

The FDA has issued a deficiency letter for NDA 217382 concerning Nutrilipid 20%. Key issues include the lack of an adequate scientific bridge between Nutrilipid 20% and Intralipid 20% due to statistically significant physicochemical differences and insufficient data on comparable drug capture capability. The application also has deficiencies in human factors validation studies, indicating unsafe user interface for critical tasks. The FDA reserves comment on proposed labeling until other issues are resolved and requests comprehensive updates to safety data, benefit-risk assessments, and clarification on the proposed indication, especially for pediatric use and non-life-threatening Local Anesthetic Systemic Toxicity (LAST).

Key points

• Provide additional data demonstrating comparable drug capture capability between Nutrilipid 20% and Intralipid 20% to establish a scientific bridge for the proposed indication.
• Provide justification as to why physicochemical differences between Nutrilipid 20% and Intralipid 20% do not affect the in vivo performance of the drug product for LAST treatment.
• Provide justification to support the applicability of safety and effectiveness data from other lipid formulations or Intralipid concentrations to Nutrilipid 20%.
• Provide detailed information regarding the published literature search strategy and methods in clinical summaries, including databases, search strings, terms, fields, dates, and inclusion/exclusion criteria.
• Provide justification for the chosen search strategy and dates.
• Provide justification for the selection and exclusion of literature references in safety and efficacy assessments, particularly for cases where lipid emulsion was not efficacious.
• Describe methods used to evaluate for duplication of case reports.
• Develop and implement additional risk controls, including device design and labeling, to address identified use errors and difficulties from the human factors validation study.

Cited reasons

• Inadequate Scientific Bridge and Clinical Literature Justification
• Human Factors Deficiencies and Risk of Medication Errors
• Deficiencies in Clinical Safety Data Presentation
• Insufficient Benefit-Risk Justification for LAST Treatment, especially in Pediatric Patients
• Discrepancies in Proposed Labeling and Indication Statement
• The FDA issued a Complete Response Letter for Nutrilipid 20% primarily due to the lack of a robust scientific bridge between Nutrilipid 20% and Intralipid 20% to support reliance on published literature for Local Anesthetic Systemic Toxicity (LAST) treatment. Significant human factors deficiencies were identified, indicating the proposed user interface does not support safe use and requires additional risk controls. Furthermore, the application requires comprehensive updates to clinical safety data presentation and a more thorough justification of the benefit-risk profile, especially for non-life-threatening LAST and pediatric populations. Minor labeling discrepancies were also noted.

Recommended actions

• Provide additional data demonstrating comparable drug capture capability between Nutrilipid 20% and Intralipid 20% to establish a scientific bridge for the proposed indication.
• Provide justification as to why physicochemical differences between Nutrilipid 20% and Intralipid 20% do not affect the in vivo performance of the drug product for LAST treatment.
• Provide justification to support the applicability of safety and effectiveness data from other lipid formulations or Intralipid concentrations to Nutrilipid 20%.
• Provide detailed information regarding the published literature search strategy and methods in clinical summaries, including databases, search strings, terms, fields, dates, and inclusion/exclusion criteria.
• Provide justification for the chosen search strategy and dates.
• Provide justification for the selection and exclusion of literature references in safety and efficacy assessments, particularly for cases where lipid emulsion was not efficacious.
• Describe methods used to evaluate for duplication of case reports.
• Develop and implement additional risk controls, including device design and labeling, to address identified use errors and difficulties from the human factors validation study.

Deficiency summary

The FDA issued a Complete Response Letter for Nutrilipid 20% primarily due to the lack of a robust scientific bridge between Nutrilipid 20% and Intralipid 20% to support reliance on published literature for Local Anesthetic Systemic Toxicity (LAST) treatment. Significant human factors deficiencies were identified, indicating the proposed user interface does not support safe use and requires additional risk controls. Furthermore, the application requires comprehensive updates to clinical safety data presentation and a more thorough justification of the benefit-risk profile, especially for non-life-threatening LAST and pediatric populations. Minor labeling discrepancies were also noted.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

NDA

Impact

Impact score

0.75

Estimated delay

270 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The Complete Response Letter highlights critical gaps in demonstrating product comparability, ensuring user safety through human factors, and providing adequate clinical data and benefit-risk justification, particularly for vulnerable populations. Labeling consistency also requires attention.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 25%